Total Valuation
Odyssey Therapeutics, Inc. has a market cap or net worth of $1.26B. The enterprise value is $610.30.
Market Cap$1.26B
Enterprise Value$610.30
Share Statistics
Odyssey Therapeutics, Inc. has 48,058,530 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding48,058,530
Owned by Insiders31.11%
Owned by Institutions53.19%
Financial Efficiency
Odyssey Therapeutics, Inc.’s return on equity (ROE) is 0.30 and return on invested capital (ROIC) is -64.44%.
Return on Equity (ROE)0.30
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-64.44%
Return on Capital Employed (ROCE)-0.66
Revenue Per Employee29.76K
Profits Per Employee-1.49M
Employee Count100
Asset Turnover0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Odyssey Therapeutics, Inc. is ―. Odyssey Therapeutics, Inc.’s PEG ratio is 0.00.
PE Ratio―
PS Ratio152.07
PB Ratio-0.93
Price to Fair Value-0.93
Price to FCF-3.46
Price to Operating Cash Flow-10.41
PEG Ratio0.00
Income Statement
In the last 12 months, Odyssey Therapeutics, Inc. had revenue of 2.98M and earned -148.65M in profits. Earnings per share was -5.39.
Revenue2.98M
Gross Profit2.98M
Operating Income-161.16M
Pretax Income-149.57M
Net Income-148.65M
EBITDA-144.65M
Earnings Per Share (EPS)-5.39
Cash Flow
In the last 12 months, operating cash flow was -75.54M and capital expenditures -334.00K, giving a free cash flow of -75.88M billion.
Operating Cash Flow-75.54M
Free Cash Flow-75.88M
Free Cash Flow per Share-1.58
Dividends & Yields
Odyssey Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.15
52-Week Price Change58.22%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)807.94K
Important Dates
Odyssey Therapeutics, Inc. upcoming earnings date is Aug 4, 2026, After Close (Confirmed).
Last Earnings DateJun 17, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
Odyssey Therapeutics, Inc. as a current ratio of 7.20, with Debt / Equity ratio of 5.89%
Current Ratio7.20
Quick Ratio7.20
Debt to Market Cap0.00
Net Debt to EBITDA0.10
Interest Coverage Ratio-9.48K
Taxes
In the past 12 months, Odyssey Therapeutics, Inc. has paid -927.00K in taxes.
Income Tax-927.00K
Effective Tax Rate<0.01
Enterprise Valuation
Odyssey Therapeutics, Inc. EV to EBITDA ratio is -3.03, with an EV/FCF ratio of -3.35.
EV to Sales147.17
EV to EBITDA-3.03
EV to Free Cash Flow-3.35
EV to Operating Cash Flow-3.38
Balance Sheet
Odyssey Therapeutics, Inc. has $310.57M in cash and marketable securities with $24.82M in debt, giving a net cash position of $285.75M billion.
Cash & Marketable Securities$310.57M
Total Debt$24.82M
Net Cash$285.75M
Net Cash Per Share$5.95
Tangible Book Value Per Share-$18.25
Margins
Gross margin is 0.00%, with operating margin of -5415.19%, and net profit margin of -4994.86%.
Gross Margin0.00%
Operating Margin-5415.19%
Pretax Margin-5026.01%
Net Profit Margin-4994.86%
EBITDA Margin-4860.42%
EBIT Margin-5025.44%
Analyst Forecast
The average price target for Odyssey Therapeutics, Inc. is $35.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$35.75
Price Target Upside39.54% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―